Beilei Wang

Postdoc
350 Shushanhu Road, Hefei, Anhui, 230031, P.R. China
Tel: +86-551-65595013
Email: beilwang@hmfl.ac.cn

 

EDUCATION BACKGROUND

2016/09—present
University of Science and Technology of China.

2008/09—2011/06
Soochow University
College of Chemistry, Chemical Engineering and Materials Science

2004/09—2008/06
Anyang Normal University
College of Chemistry, Chemical Engineering and Materials Science

 

WORK EXPERIENCE

2013/10—present

High Magnetic Field Laboratory, Chinese Academy of Sciences

2012/05—2013/10

City University of Hong Kong, Department of Biology and Chemistry

Publications

  1. Bei-Lei Wang#, Nai-Kai Li, Jin-Xin Zhang, Guo-Gui Liu, Teng Liu, Qi Shen, and Xing-Wing Wang*. Dinuclear Zinc Catalyzed Asymmetric Friedel-Crafts Amidoalkylation of Indoles with Aryl Aldimines, Organic & Biomolecular Chemistry, Org. Biomol. Chem. 2011, 9: 2614-2617.
  2. Bei-Lei Wang#, Jin-X Zhang, Nai-Kai Li, Guo-Gui Liu, Qi Shen, Xing-Wang Wang*. Organic Phosphite and Phosphoric Acid Efficiently Catalyzed Friedel-Crafts Amidoalkylation of Indoles with Aryl Aldimines, Tetra. Lett. 2011, 52: 4671-4674.
  3. Beilei Wang#, Hui Qian, Shek-Man Yiu, Jianwei Sun, and Guangyu Zhu*. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor. Eur. J. Med. Chem. 2013, 1: 366-373. doi.org/10.1016/j.ejmech.2013.10.062.
  4. Beilei Wang#, Zhigang Wang, Fujin Ai, Wai Kin Tang, and Guangyu Zhu*. A monofunctional platinum(II)-based anticancer agent from a salicylanilide derivative: Synthesis, antiproliferative activity, and transcription inhibition. J. Inorg. Biochem. 2014, 142C: 118-125.
  5. Hong Wu#, Aoli Wang#, Wei Zhang#, Beilei Wang#, Cheng Chen,Wenchao Wang, Chen Hu, Zi Ye, Zheng Zhao, Li Wang, Xixiang Li, Kailin Yu,Juan Liu, Jiaxin Wu, Xiao-E Yan, Peng Zhao, Jinhua Wang, Chu Wang,Ellen L. Weisberg, Nathanael S. Gray*, Cai-Hong Yun*, Jing Liu*, Liang Chen*, Qingsong Liu*. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells, Oncotarget 2015, 6: 31313–31322.
  6. Xiaofei Liang#, Xiaochuan Liu#, Beilei Wang#, Fengming Zou#, Aoli Wang, Shuang Qi, Cheng Chen, Zheng Zhao, Wenchao Wang, Ziping Qi, Fengchao Lv, Zhenquan Hu, Li Wang, Shanchun Zhang, Qingsong Liu*, Jing Liu*. Discovery of 2-((3-amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a potent, selective and orally available BCR-ABL/SRC/p38 kinase inhibitor for Chronic Myeloid Leukemia, J. Med. Chem. 2016, 59: 1984–2004.
  7. Zhilong Chen#, Beilei Wang, Zhaobin Wang, Guangyu Zhu,* and Jianwei Sun*. Complex bioactive alkaloid-type polycycles through efficient catalytic asymmetric multicomponent aza-diels-alder reaction of indoles with oxetane as directing group. Angew. Chem. Int. Ed. 2013, 52, 2027-2031.
  8. Xianfeng Chen#*, Guangyu Zhu*, Yang Yang ,Beilei Wang, Li Yan , Kenneth Yin Zhang , Kenneth Kam-Wing Lo , and Wenjun Zhang*. A diamond nanoneedle patch for potential high-throughput intracellular delivery. Adv. Healthcare Mater. 2013, 2: 1103-1107.
  9. Li Yan#, Anthony P. Raphael , Xiaoyue Zhu , Beilei Wang, Wei Chen , Tao Tang , Yan Deng , Himanshu J. Sant , Guangyu Zhu , Kwong Wai Choy , Bruce K. Gale , Tarl W. Prow , and Xianfeng Chen*. Nanocomposite strengthened dissolving microneedles for improved transdermal delivery to human skin. Adv. Healthcare Mater. 2013, 3: 555-564. DOI: 10.1002/adhm.201300312.
  10. Hongli Wen#, Hai Zhu, Xian Chen, Tak Fu Hung, Beilei Wang, Guangyu Zhu*, Fung Yu, Feng Wang*. Upconverting near-infrared light through energy management in core-shell-shell nanoparticles. Angew. Chem. Intl. Ed. 2013, 52: 13419-13423.
  11. Hong Wu#, Wenchao Wang#, Feiyang Liu#, Ellen E. Weisberg, Bei Tian, Yongfei Chen, Binhua Li, Aoli Wang , Beilei Wang, Zheng Zhao, Douglas W. McMillin, Chen Hu, Hong Li, Jinhua Wang, Yanke Liang, Sara J. Buhrlage, Junting Liang, Jing Liu*, Guang Yang, Jennifer R. Brown, Steven P. Treon, Constantine S. Mitsiades, James Griffin, Qingsong Liu*, Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma. ACS Chem. Biol. 2014, 9: 1086–1091.
  12. Xixiang Li#, Aoli Wang#, Kailin Yu#, Ziping Qi#, Cheng Chen, Wenchao Wang, Chen Hu, Hong Wu, Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Li Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu*, Liu Qingsong*. Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. J. Med. Chem. 2015, 58: 9625–9638.
  13. Hong Wu#, Chen Hu#, Aoli Wang#, Ellen L. Weisberg#, Yongfei Chen#, Cai-Hong Yun, Wenchao Wang, Yan Liu, Xiaochuan Liu, Bei Tian, Jinhua Wang, Zheng Zhao, Yanke Liang, Binhua Li, Li Wang, Beilei Wang, Cheng Chen, Sara J. Buhrlage, Ziping Qi, Fengming Zou, Atsushi Nonami, Yuyang Li, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Xianhuo Wang, Guang Yang, James D. Griffin, Jennifer R. Brown, Michael J. Eck, Jing Liu*, Nathanael S. Gray*, Liu Qingsong*. Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia. Leukemia 2016, 30: 173–181.
  14. Hong Wu#, Chen Hu#, Aoli Wang#, Ellen L. Weisberg#, Wenchao Wang1, Cheng Chen, Zheng Zhao, Kailin Yu, Juan Liu, Jiaxin Wu, Atsushi Nonami, Li Wang, Beilei Wang, Richard M. Stone, Suiyang Liu, James D. Griffin, Jing Liu*, Qingsong Liu*. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia 2016, 30: 754–757.
  15. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Cheng Chen, Xiaochuan Liu, Aoli Wang, Shuang Qi, Wenchao Wang, Ziping Qi, Zheng Zhao, Zhenquan Hu, Wei Wang, Wang Li, Shanchun Zhang, Yuexiang Wang, Jing Liu*, Qingsong Liu *. Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). J. Med. Chem. 2016, 59: 3964–3979.
  16. Feiyang Liu#, Beilei Wang#, Qiang Wang#, Ziping Qi#, Cheng Chen, Lu-Lu Kong, Ji-Yun Chen, Xiaochuan Liu, Aoli Wang, Chen Hu, Wenchao Wang, Huiping Wang, Fan Wu, Yanjie Ruan, Shuang Qi, Juan Liu, Fengming Zou, Zhenquan Hu, Wei Wang, Li Wang, Shanchun Zhang, Cai-Hong Yun, Zhimin Zhai, Jing Liu*, Qingsong Liu*. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML). Oncotarget 2016, 7: 45562-45574.
  17. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Ziping Qi, Cheng Chen, Kailin Yu, Chen Hu, Shuang Qi, Wenchao Wang, Zhenquan Hu, Juan Liu, Wei Wang, Li Wang, Qianmao Liang, Shanchun Zhang, Tao Ren, Qingsong Liu*, Jing Liu*. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J. Med. Chem. 2017, 60: 273–289.
  18. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Cheng Chen#, Juanjuan Liu, Zheng Zhao, Hong Wu, Yuanxin Deng, Wang Li, Beilei Wang, Jiaxin Wu, Feiyang Liu, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, James D. Griffin, Shanchun Zhang, Teckpeng Loh, Xin Zhang, Wenchao Wang*, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN-015) for B-Cell malignances. Oncotarget 2016, 7: 32641-51.
  19. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Juanjuan Liu#, Fengming Zou#, Cheng Chen, Zheng Zhao, Yuanxin Deng, Hong Wu, Ziping Qi, Beilei Wang, Li Wang, Feiyang Liu, Yunhe Xu, Wenchao Wang, Stacey M. Fernandes, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, Teckpeng Loh, James. D. Griffin, Shanchun Zhang, Ellen L. Weisberg*, Xin Zhang*, Jing Liu*, Qingsong Liu*. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies. Oncotarget 2016, 7: 53515-53525.
  20. Binhua Li#, Aoli Wang#, Juan Liu#, Ziping Qi#, Xiaochuan Liu#, Kailin Yu, Hong Wu, Cheng Chen, Chen Hu, Wenchao Wang, Jiaxin Wu, Zhenquan Hu, Ling Ye, Fengming Zou, Feiyang Liu, Beilei Wang, Li Wang, Tao Ren, Shaojuan Zhang, Mingfeng Bai, Shanchun Zhang, Jing Liu*, Qingsong Liu*. Discovery of N-((1-(4-(3-(3-((6,7-dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase. J. Med. Chem. 2016, 59: 8456−8472.
  21. Aoli Wang#, Xiao-E Yan#, Hong Wu#, Wenchao Wang#, Chen Hu, Cheng Chen, Zheng Zhao, Peng Zhao, Xixiang Li, Li Wang, Beilei Wang, Zi Ye, Jinhua Wang, Chu Wang, Wei Zhang, Nathanael S. Gray, Ellen L. Weisberg, Liang Chen, Jing Liu*, Cai-Hong Yun*, Qingsong Liu*. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget 2016, 7: 69760-69769.
  22. Xiaofei Liang#, Fengchao Lv#, Beilei Wang#, Kailin Yu#, Hong Wu, Ziping Qi, Zongru Jiang, Cheng Chen, Aoli Wang, Weili Miao, Wenchao Wang, Zhenquan Hu, Juan Liu, Xiaochuan Liu, Zheng Zhao, Li Wang, Shanchun Zhang, Zi Ye, Chu Wang, Tao Ren, Yinsheng Wang, Qingsong Liu*, Jing Liu*. Discovery of 2-((3-acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. J. Med. Chem. 2017, 60: 1793–1816.
  23. Aoli Wang#, Xixiang Li#, Hong Wu#, Fengming Zou#, Xiao-E Yan, Cheng Chen, Chen Hu, Kailin Yu, Wenchao Wang, Peng Zhao, Jiaxin Wu, Ziping Qi, Wei Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, Qingsong Liu*. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutants Kinase Inhibitor with a Distinct Binding Mode. J. Med. Chem. , 2017. DOI: 10.1021/acs.jmedchem.6b01907.

Patents

  1. 贾俊，王蓓蕾，王兴旺，一种3-吲哚芳基甲磺酰胺的制备方法，2011.10.07，CN201110076928.4.
  2. 刘青松，刘静，王蓓蕾，王傲莉，吴宏，胡晨，王文超，陈程，王黎，李希祥，依鲁替尼的新用途，2014.10.25，201410258423.3.
  3. 刘青松，刘静，王强，王蓓蕾，刘飞扬，亓爽，齐紫平，邹凤鸣，陈程，王文超，胡晨，刘晓川，王伟，王傲莉，王黎，胡祯全，任涛，一种选择性的C-KIT激酶抑制剂，2201610210424.X.
  4. 刘静，刘青松，梁小飞，王蓓蕾，王傲莉，刘晓川，陈程，齐紫平，王文超，赵铮，王黎,一种新型的BCR-ABL激酶抑制剂， 201510172534.7.
  5. 刘青松，刘静，王强，刘飞扬，王蓓蕾，王傲莉，王文超，胡晨，陈程，赵铮，吴宏，王黎，一种新型结构的激酶抑制剂，201410757626.7.
  6. 刘青松，刘静，陈永飞，吴宏，王傲莉，王蓓蕾，胡晨，王文超，陈程，一种新型Bruton酪氨酸激酶抑制，201410280931.1.